Quote Overview

Stock Activity

Open	47.07
Day Low	47.00
Day High	48.38
52 Wk Low	42.63
52 Wk High	57.82
Avg. Volume	2,152,752
Market Cap	119.27 B
Dividend	1.38 ( 2.92%)
Beta	0.61

Key Earnings Data

Earnings ESP	-3.09%
Most Accurate Est	0.94
Current Qtr Est	0.97
Current Yr Est	4.11
Exp Earnings Date	^*BMO4/25/24
Prior Year EPS	4.39
Exp EPS Growth (3-5yr) 6.95%
Forward PE	11.48
PEG Ratio	1.65

Medical » Large Cap Pharmaceuticals

*BMO = Before Market Open *AMC = After Market Close

Research Reports for SNY

All Zacks’ Analyst Reports

Premium Research for SNY

Style Scores A Value B Growth F Momentum B VGM
Zacks Rank	Sell 4
Zacks Industry Rank	Bottom 21%(199 out of 252)
Zacks Sector Rank	Top 25% (4 out of 16)
Earnings ESP	-3.09%
Research Reports for SNY Analyst \| Snapshot

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Premium Research: Industry Analysis

Top Peers	Symbol	Zacks Rank
Sanofi	SNY
AbbVie	ABBV
AstraZeneca	AZN
Eli Lilly	LLY
Johnson & Johnson	JNJ
Merck & Co.	MRK
Novartis	NVS

See all Large Cap Pharmaceuticals Peers

Zacks News for SNY

No Record found.

Company Summary

Sanofi, located in Paris, France, manufactures and markets prescription drugs in Europe, the United States and other countries. It focuses on major therapeutic areas such as immunology, neurology, oncology, rare disease, rare blood disorders and diabetes, among others.

In April 2011, Genzyme Corporation became a subsidiary of Sanofi. The deal added products like Cerezyme, Myozyme/Lumizyme and Fabrazyme in its portfolio. Sanofi swapped its Merial Animal Health businesses with Boehringer Ingelheim’s Consumer Healthcare (CHC) business in January 2017. With the acquisition of Chattem in 2010, Sanofi became a major player in the CHC sector. Other smaller acquisitions in the past few years include Ablynx and Bioverativ in 2018, Synthorx and Principia in 2020, Translate Bio and Kadmon in 2021 and Provention Bio in 2023.

Sanofi has collaboration agreements with companies like Regeneron among others. Sanofi has developed and markets Dupixent and Kevzara in collaboration with Regeneron. Initially the companies also co-marketed Praluent and Libtayo. However, from April 2020, the agreement was restructured. Sanofi is now solely responsible for Praluent marketing in outside U.S. markets while Regeneron has the sole responsibility for Praluent in the United States. In 2022, Sanofi also restructured its immuno-oncology collaboration with Regeneron regarding Libtayo by granting them the worldwide exclusive license rights of the drug.

Sanofi’s Biopharma segment comprises three operating segments: Specialty Care (Dupixent, neurology & immunology, rare diseases, rare blood disorders, and oncology), Vaccines and General Medicines (diabetes, cardiovascular, and established products). The company’s Consumer Healthcare (CHC) was established as a standalone business unit in 2019. In October, Sanofi announced it intends to separate the CHC unit through the creation of a publicly-listed entity headquartered in Paris. The separation is not expected to happen before the fourth quarter of 2024.

In 2023, total sales rose 5.4% (at CER) to €43.0 billion. Specialty Care accounted for 41.9% while General Medicines accounted for 28.7% of the company’s total sales. Vaccines accounted for 17.3% of total sales. The CHC unit accounted for 12.1% of 2023 total sales.